Exchange: NASDAQ·Updated 04:18 PM EDT
News
all
press releases
Schrdinger to Present at Morgan Stanley Global Healthcare Conference
Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the Investors...
Business Wire
More News
When The Rule Of Law Fails
When The Rule Of Law Fails Authored by Madge Waggy, What follows emerges from seventeen months of examination into procedural collapses, constitutional erosions, and institutional betrayals that have accelerated beyond the capacity of conventional reportage to capture. Sources include...
Zero Hedge
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Zacks
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Zacks
Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrdinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the companys common stock to two newly hired employees. These grants were made pursuant to the companys 2021 Inducement Equity Incentive Plan...
Business Wire
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates
Schrodinger (SDGR) delivered earnings and revenue surprises of +113.33% and +15.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Schrdinger Reports Second Quarter 2026 Financial Results
Schrdinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended June 30, 2026. We are very pleased with our second quarter results, delivering ACV of $29.6 million, which represents 27% growth. Our results reflect growing industry adoption of a predict-first approach to...
Business Wire
Schrdinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
Schrdinger, Inc. (Nasdaq: SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrdinger's agentic AI co-scientist, within its research organization. Building on a long-standing partnership with BMS where they routinely utilize Schrdingers industry-leading...
Business Wire
Schrdinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
Schrdinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies, execute sophisticated molecular discovery workflows and interpret results. By...
Business Wire
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers PR Newswire NEW YORK...
PR Newswire

Advertisement|Remove ads.